Huntington Bancshares Incorporated (NASDAQ:HBAN) Director Richard W. Neu bought 15,100 shares of the stock on the open market in a transaction that occurred on Tuesday, May 6th. The stock was purchased at an average cost of $9.04 per share, with a total value of $136,504.00. Following the purchase, the director now directly owns 125,094 shares of the company’s stock, valued at approximately $1,130,850.Huntington Bancshares Incorporated (NASDAQ:HBAN) net profit margin is 32.40% and weekly performance is 1.32%. On last trading day company shares ended up $9.20. Analysts mean target price for the company is $ 10.21. Huntington Bancshares Incorporated (NASDAQ:HBAN) distance from 50-day simple moving average (SMA50) is -3.87%.
Quest Diagnostics Inc (NYSE:DGX) CFO Mark Guinan purchased 4,000 shares of the stock on the open market in a transaction dated Monday, May 5th. The stock was purchased at an average cost of $55.51 per share, for a total transaction of $222,040.00. Following the completion of the purchase, the chief financial officer now directly owns 44,222 shares of the company’s stock, valued at approximately $2,454,763.Quest Diagnostics Inc (NYSE:DGX) shares advanced 2.45% in last trading session and ended the day on $57.27. DGX Gross Margin is 39.30% and its return on assets is 10.40%. Quest Diagnostics Inc (NYSE:DGX) quarterly performance is 12.78%.
Masco Corporation (NYSE:MAS) Director Christopher A. O’herlihy bought 3,000 shares of the stock on the open market in a transaction dated Tuesday, May 6th. The shares were purchased at an average price of $20.11 per share, for a total transaction of $60,330.00. Following the transaction, the director now directly owns 10,900 shares in the company, valued at approximately $219,199.Masco Corporation (NYSE:MAS) shares moved up 0.10% in last trading session and was closed at $19.73, while trading in range of $19.64 – $20.19. Masco Corporation (NYSE:MAS) year to date (YTD) performance is -12.78%.
Aegerion Pharmaceuticals Inc (NASDAQ:AEGR) CEO Marc D. Beer acquired 30,000 shares of the stock on the open market in a transaction that occurred on Thursday, May 8th. The shares were purchased at an average price of $35.31 per share, with a total value of $1,059,300.00. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) ended the last trading day at $32.99. Company weekly volatility is calculated as 8.64% and price to cash ratio as 7.71. Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR) showed a negative weekly performance of -27.54%.